- Home
- NUVL vs GPI Comparison
NUVL vs GPI Comparison
Compare NUVL & GPI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- GPI
- Stock Information
- Founded
- NUVL 2017
- GPI 1995
- Country
- NUVL United States
- GPI United States
- Employees
- NUVL N/A
- GPI N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- GPI Retail-Auto Dealers and Gas Stations
- Sector
- NUVL Health Care
- GPI Consumer Discretionary
- Exchange
- NUVL Nasdaq
- GPI Nasdaq
- Market Cap
- NUVL 5.6B
- GPI 5.3B
- IPO Year
- NUVL 2021
- GPI 1997
- Fundamental
- Price
- NUVL $73.48
- GPI $406.52
- Analyst Decision
- NUVL Strong Buy
- GPI Strong Buy
- Analyst Count
- NUVL 8
- GPI 8
- Target Price
- NUVL $115.50
- GPI $453.00
- AVG Volume (30 Days)
- NUVL 682.1K
- GPI 209.0K
- Earning Date
- NUVL 05-08-2025
- GPI 04-24-2025
- Dividend Yield
- NUVL N/A
- GPI 0.49%
- EPS Growth
- NUVL N/A
- GPI N/A
- EPS
- NUVL N/A
- GPI 35.64
- Revenue
- NUVL N/A
- GPI $20,969,100,000.00
- Revenue This Year
- NUVL N/A
- GPI $12.69
- Revenue Next Year
- NUVL N/A
- GPI $4.40
- P/E Ratio
- NUVL N/A
- GPI $11.41
- Revenue Growth
- NUVL N/A
- GPI 15.13
- 52 Week Low
- NUVL $55.54
- GPI $279.86
- 52 Week High
- NUVL $113.51
- GPI $490.09
- Technical
- Relative Strength Index (RSI)
- NUVL 54.91
- GPI 52.17
- Support Level
- NUVL $71.60
- GPI $379.99
- Resistance Level
- NUVL $74.28
- GPI $425.56
- Average True Range (ATR)
- NUVL 4.86
- GPI 19.94
- MACD
- NUVL 1.08
- GPI 3.14
- Stochastic Oscillator
- NUVL 95.73
- GPI 66.49
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About GPI Group 1 Automotive Inc.
Group 1 owns and operates 39 collision centers and 258 automotive dealerships in the US and the UK, offering 35 brands of automobiles altogether. Slightly over half of the stores are in the US with locations mostly in metropolitan areas in 17 states in the Northeast, Southeast, Midwest, and California. Texas alone contributed 33.5% of new-vehicle unit volume in 2024 and the UK 22.6%. Texas, Massachusetts, and California combined was 48.5%. Revenue in 2024 totaled $19.9 billion. The August 2024 Inchcape UK deal adds about $2.7 billion of annual revenue and 54 stores to bring the UK store count to 114. The firm entered the UK in 2007. Group 1 was founded in 1995 and is based in Houston.